Cytosorbents (CTSO) AI Stock Analysis

• Market Cap: $49.66M
• Dividend Yield: N/A
• Average Volume (3M): 76.80K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -8.97%
• EPS Growth: 47.29%
• Country: US
• Employees: 149
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.04
• Shares Outstanding: 62,761,806
• 10 Day Avg. Volume: 63,287
• 30 Day Avg. Volume: 76,802
• PEG Ratio: 0.06
• Price to Book (P/B): 4.46
• Price to Sales (P/S): 1.39
• P/FCF Ratio: -3.37
• Enterprise Value/Market Cap: 2.08
• Enterprise Value/Revenue: 3.08
• Enterprise Value/Gross Profit: 4.24
• Enterprise Value/Ebitda: -5.39
• 1Y Price Target: $0.75
• Price Target Upside: 13.64% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $0.50 ▼(-24.24% Downside)

Cytosorbents' stock score is primarily impacted by its challenging financial performance and bearish technical indicators. The company's high leverage and negative cash flows pose significant risks. Despite some positive developments in revenue growth and strategic initiatives, the overall outlook remains cautious due to ongoing profitability challenges and weak valuation metrics.

Positive Factors

Revenue Growth

The 10% revenue growth indicates strong demand for CytoSorbents' products, suggesting potential for continued market expansion and increased adoption.

Gross Margin Improvement

Improved gross margins reflect efficient cost management and pricing power, contributing to better profitability potential over the long term.

Strategic Cost Reductions

The strategic cost reduction plan aims to optimize operations and improve financial health, positioning the company for sustainable profitability.

Negative Factors

High Leverage

High leverage increases financial risk and limits flexibility, potentially impacting the company's ability to invest in growth or weather economic downturns.

Negative Cash Flow

Negative cash flow poses liquidity challenges and may hinder the company's ability to fund operations and growth initiatives without external financing.

Profitability Challenges

Ongoing profitability issues suggest difficulties in achieving sustainable earnings, which could affect long-term viability and investor confidence.

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology. Its flagship product is CytoSorb, an extracorporeal cytokine filter for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention and treatment of perioperative complications of cardiopulmonary bypass surgery, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant. The company also develops VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals; CytoSorb-XL, a device for adjunctive therapy in the treatment of sepsis and other critical illnesses; HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients, as well as removal of anti-A and anti-B blood group antibodies from fresh whole blood and plasma; K+ontrol for treatment of severe hyperkalemia in patients with life-threatening conditions; and ContrastSorb for the removal of IV contrast in blood administered during CT imaging, an angiogram, or during a vascular interventional radiology procedure to reduce the risk of contrast-induced nephropathy. In addition, it is involved in the development of BetaSorb, a device for the prevention and treatment of health complications caused by the accumulation of metabolic toxins in patients with chronic renal failure; DrugSorb, a device to remove toxic chemicals from the blood; and DrugSorb-ATR, an antithrombotic removal system. The company was formerly known as MedaSorb Technologies Corporation and changed its name to Cytosorbents Corporation in May 2010. Cytosorbents Corporation was founded in 1997 and is headquartered in Princeton, New Jersey.

How the Company Makes Money

Cytosorbents generates revenue primarily through the sale of its CytoSorb devices and related products to hospitals and healthcare providers. The company employs a direct sales model in certain markets, while also working with distributors and partners to expand its reach. Key revenue streams include the sale of disposable CytoSorb cartridges, which are used in conjunction with the device for blood purification during critical care treatments. The company has established significant partnerships with medical institutions and research organizations, which not only enhance its product visibility but also facilitate clinical studies that can lead to broader adoption of its technologies. Additionally, Cytosorbents may explore opportunities for reimbursement from healthcare payers, further contributing to its earnings potential.

Cytosorbents Financial Statement Overview

Summary

Cytosorbents is facing significant financial challenges with consistent losses and high leverage. While there is some revenue growth and strong gross profit margins, the company's profitability and cash flow positions are concerning. High debt levels and negative cash flows highlight potential risks, necessitating strategic adjustments to improve financial health.

Income Statement

Cytosorbents has shown a slight improvement in revenue growth with a TTM growth rate of 2.37%. However, the company continues to face significant profitability challenges, as indicated by negative net profit and EBIT margins. The gross profit margin remains strong at 72.57%, suggesting efficient cost management at the production level, but overall profitability is hindered by high operating expenses.

Balance Sheet

The company's balance sheet reflects high leverage with a debt-to-equity ratio of 2.34, indicating a reliance on debt financing. The return on equity is negative, highlighting ongoing losses. The equity ratio stands at 24.14%, suggesting a moderate level of equity financing relative to total assets, but the high debt levels pose a risk to financial stability.

Cash Flow

Cytosorbents is experiencing negative operating and free cash flows, with a declining free cash flow growth rate of -24.67% in the TTM period. The operating cash flow to net income ratio is close to 1, indicating that cash flow generation is in line with net losses, but the overall cash flow situation remains weak, posing liquidity challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	33.48M	35.59M	31.08M	34.69M	40.11M	39.45M
Gross Profit	24.30M	25.13M	21.95M	20.73M	29.06M	28.40M
EBITDA	-19.14M	-15.22M	-27.88M	-30.00M	-21.62M	-9.71M
Net Income	-9.75M	-20.72M	-29.25M	-32.81M	-24.56M	-7.84M
Balance Sheet
Total Assets	47.99M	47.37M	53.26M	63.23M	89.52M	89.95M
Cash, Cash Equivalents and Short-Term Investments	10.20M	3.28M	14.13M	22.14M	52.14M	71.42M
Total Debt	27.06M	26.89M	18.31M	18.25M	13.82M	1.03M
Total Liabilities	36.40M	36.26M	29.99M	27.86M	26.94M	10.73M
Stockholders Equity	11.59M	11.11M	23.28M	35.38M	62.58M	79.22M
Cash Flow
Free Cash Flow	-10.29M	-14.71M	-22.59M	-34.69M	-18.29M	-7.29M
Operating Cash Flow	-9.78M	-14.43M	-21.66M	-28.23M	-14.01M	-5.61M
Investing Cash Flow	-601.55K	-669.43K	-936.24K	-6.46M	-4.28M	-1.68M
Financing Cash Flow	6.90M	9.33M	14.47M	4.96M	715.20K	66.35M

Cytosorbents Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.66
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Negative. The current price of 0.66 is below the 20-day moving average (MA) of 0.77, below the 50-day MA of 0.87, and below the 200-day MA of 0.98, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 27.46 is Positive, neither overbought nor oversold. The STOCH value of 22.88 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CTSO.

Cytosorbents Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XTNT	65 Neutral	$103.88M	-20.78	3.64%	―	16.88%	―
SRTS	64 Neutral	$70.96M	―	-5.71%	―	-13.79%	-132.21%
FONR	59 Neutral	$92.82M	13.30	4.34%	―	3.36%	-21.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
HYPR	50 Neutral	$96.28M	-1.97	-94.03%	―	-20.10%	7.87%
NSPR	48 Neutral	$88.66M	-2.52	-87.61%	―	14.04%	-0.65%
CTSO	38 Underperform	$49.66M	-4.34	-96.15%	―	-8.97%	47.29%

Cytosorbents Corporate Events

CytoSorbents Reports Strong Q3 2025 Growth and Strategic Advances

CytoSorbents Corporation is a company specializing in blood purification technologies, primarily used in intensive care units and cardiac surgery to treat life-threatening conditions. In its third-quarter 2025 financial report, CytoSorbents announced a 10% year-over-year revenue increase, reaching $9.5 million, driven by strong performance in distributor territories and direct sales outside Germany. The company also reported an improved gross margin of 70% and a reduced operating loss of $2.9 million compared to the previous year.

Cytosorbents Corp’s Latest Study Update: A Game Changer in Critical Care?

Study Overview: The CytOSorb TreatMent Of Critically Ill PatientS Registry is an international observational study aimed at creating a comprehensive data repository to monitor the use of the CytoSorb device in real-world critical care settings. This registry seeks to enhance the quality of patient care by providing a scientifically-based resource for measuring and improving treatment outcomes in conditions such as septic shock, acute respiratory distress syndrome, and more.

CytoSorbents’ STAR Registry: A Closer Look at the Latest Clinical Study Update

The Safe and Timely Antithrombotic Removal (STAR) Registry is an international observational study conducted by CytoSorbents Corp. Its primary aim is to document real-world clinical use and outcomes of the CytoSorb device, specifically for removing antithrombotic agents in acute hospital settings. This study is significant as it addresses critical conditions such as surgical and postoperative hemorrhage, providing insights into the device’s effectiveness and safety.

Cytosorbents Faces Nasdaq Non-Compliance Notice

On October 2, 2025, CytoSorbents Corporation received a notice from Nasdaq for non-compliance with the Minimum Bid Price Requirement, as its stock price remained below $1.00 for 30 consecutive business days. The company has until March 31, 2026, to regain compliance by ensuring its stock price meets or exceeds $1.00 for at least 10 consecutive days. Failure to comply could lead to an additional compliance period if an acceptable plan is presented to Nasdaq. The company is actively monitoring its stock price and exploring options to meet the requirement.

The most recent analyst rating on (CTSO) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Cytosorbents stock, see the CTSO Stock Forecast page.